Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies; and partnership with Phyton Biotech. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone781-674-4400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$36.78 million
Profitability
Miscellaneous
Employees255
Next Earnings Date5/6/2019 (Estimated)
OptionableOptionable
Agenus (NASDAQ:AGEN) Frequently Asked Questions
What is Agenus' stock symbol?
Agenus trades on the NASDAQ under the ticker symbol "AGEN."
How were Agenus' earnings last quarter?
Agenus Inc (NASDAQ:AGEN) released its earnings results on Thursday, March, 14th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.12. The biotechnology company earned $5.36 million during the quarter, compared to analysts' expectations of $6.67 million. View Agenus' Earnings History.
When is Agenus' next earnings date?
Has Agenus been receiving favorable news coverage?
Media stories about AGEN stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Agenus earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Agenus' key competitors?
Some companies that are related to Agenus include Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX), Alector (ALEC), Rubius Therapeutics (RUBY), Iovance Biotherapeutics (IOVA), Editas Medicine (EDIT), Fate Therapeutics (FATE), Coherus Biosciences (CHRS), Autolus Therapeutics (AUTL), Sangamo Therapeutics (SGMO), BioCryst Pharmaceuticals (BCRX), Vericel (VCEL), Cellectis (CLLS), NanoString Technologies (NSTG) and Nightstar Therapeutics (NITE).
What other stocks do shareholders of Agenus own?
Who are Agenus' key executives?
Agenus' management team includes the folowing people:
- Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 66)
- Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 53)
- Dr. Alexander R. Duncan, CTO & Head of Research (Age 57)
- Dr. Robert B. Stein, Sr. R&D Advisor (Age 68)
- Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 51)
Who are Agenus' major shareholders?
Agenus' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include RTW Investments LP (8.45%), BlackRock Inc. (5.71%), D. E. Shaw & Co. Inc. (2.06%), Northern Trust Corp (0.91%), Geode Capital Management LLC (0.89%) and Geode Capital Management LLC (0.89%). Company insiders that own Agenus stock include Alex Duncan, Christine M Klaskin, Garo H Armen and Karen Valentine. View Institutional Ownership Trends for Agenus.
Which major investors are selling Agenus stock?
AGEN stock was sold by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Northern Trust Corp, Virtus ETF Advisers LLC, Barclays PLC, California Public Employees Retirement System, Virtu Financial LLC and Principal Financial Group Inc.. View Insider Buying and Selling for Agenus.
Which major investors are buying Agenus stock?
AGEN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., D. E. Shaw & Co. Inc., Millennium Management LLC, RTW Investments LP, Geode Capital Management LLC, Geode Capital Management LLC, Two Sigma Investments LP and Bank of New York Mellon Corp. View Insider Buying and Selling for Agenus.
How do I buy shares of Agenus?
Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agenus' stock price today?
One share of AGEN stock can currently be purchased for approximately $2.98.
How big of a company is Agenus?
Agenus has a market capitalization of $399.95 million and generates $36.78 million in revenue each year. The biotechnology company earns $-162,040,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Agenus employs 255 workers across the globe.
What is Agenus' official website?
How can I contact Agenus?
Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]
MarketBeat Community Rating for Agenus (NASDAQ AGEN)
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
